Will the dot-com bubble crash be re-enacted? | Lee Jae-chan, Hana Securities Myeongdong Financial Center PB [Double Crew]

Watch on YouTube ↗  |  May 26, 2026 at 01:08  |  18:21  |  3PRO TV (삼프로TV)
Speakers
Lee Jae-chan — Deputy Manager

Summary

Lee Jae-chan from Hana Securities argues that the current market at KOSPI 8000 is not a bubble like the dot-com era, citing sustained AI capex. He recommends focusing on AI infrastructure (semiconductors, nuclear, solar) as the core portfolio. For alpha, he suggests allocating 10-20% to KOSDAQ medical device stocks, particularly skin beauty names, and highlights Pharmaresearch, Curiox, and other small-cap plays.

  • Lee Jae-chan believes the market is still mid-cycle and not due for a crash.
  • AI infrastructure capex is not declining, supporting further upside.
  • Oil and rates are headwinds but not terminal for the rally.
  • KOSDAQ medical device sector offers high operating margins and global growth.
  • Pharmaresearch may rebound on improving cosmetics margins.
  • Curiox has a novel serum separation technology with ten-bagger potential.
  • Super Rookie names are interesting but not yet actionable.
  • The host and guest agree on a portfolio split of 70-80% leading sectors and 10-20% medical devices.
Trade Ideas
Lee Jae-chan Deputy Manager 3:00
Stay long AI semiconductor supply chain.
AI capex is not declining, AI monetization has not failed, and the market is still mid-cycle despite oil and rate headwinds. Investors should focus on AI infrastructure including DRAM, nuclear power, and solar power.
Lee Jae-chan Deputy Manager 7:46
Buy Korean medical device stocks.
KOSDAQ medical device stocks, especially skin beauty names like Pharmaresearch, Hugel, and Classys, have operating margins around 40% and benefit from rising global demand for Korean beauty procedures. Allocating 10-20% of a portfolio to this sector can provide attractive alpha.
Lee Jae-chan Deputy Manager 9:06
Pharmaresearch rebound on cosmetics margin.
Pharmaresearch has a strong brand (Rejuran) but faced multiple compression due to competition from L&C Bio's new product. Improvement in its cosmetics division margins should drive a rebound in the stock.
Lee Jae-chan Deputy Manager 16:28
Curiox new standard in serum separation.
Curiox has developed a novel non-centrifuge serum separation technology that could become a new standard adopted by big pharma, giving it ten-bagger potential.
Up Next

This 3PRO TV (삼프로TV) video, published May 26, 2026, features Lee Jae-chan discussing SMH, KOSDAQ medical device stocks, 214450.KQ, Curiox. 4 trade ideas extracted by AI with direction and confidence scoring.

Speakers: Lee Jae-chan  · Tickers: SMH, KOSDAQ medical device stocks, 214450.KQ, Curiox